Identification

Name
Delamanid
Accession Number
DB11637
Type
Small Molecule
Groups
Approved, Investigational
Description

Delamanid is an anti-tuberculosis agent derived from the nitro-dihydro-imidazooxazole class of compounds that inhibits mycolic acid synthesis of bacterial cell wall [1]. It is used in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis (TB) in a combination regimen. Emergence of multidrug-resistant and extensively drug-resistant tuberculosis creates clinical challenges for patients, as the disease is associated with a higher mortality rate and insufficient therapeutic response to standardized antituberculosis treatments as Isoniazid and Rifampicin. Multidrug-resistant tuberculosis may also require more than 2 years of chemotherapy and second-line therapies with narrow therapeutic index [4]. In a clinical study involving patients with pulmonary multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis, treatment of delamanid in combination with WHO-recommended optimised background treatment regimen was associated with improved treatment outcomes and reduced mortality rate [1]. Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [6]. Delamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan).

Structure
Thumb
Synonyms
Not Available
External IDs
OPC 67683 / OPC-67683
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DeltybaTablet, film coated50 mgOralOtsuka Novel Products Gmb H2014-04-28Not applicableEu
DeltybaTablet, film coated50 mgOralOtsuka Novel Products Gmb H2014-04-28Not applicableEu
DeltybaTablet, film coated50 mgOralOtsuka Novel Products Gmb H2014-04-28Not applicableEu
DeltybaTablet, film coated50 mgOralOtsuka Novel Products Gmb H2014-04-28Not applicableEu
Categories
UNII
8OOT6M1PC7
CAS number
681492-22-8
Weight
Average: 534.492
Monoisotopic: 534.17261903
Chemical Formula
C25H25F3N4O6
InChI Key
XDAOLTSRNUSPPH-XMMPIXPASA-N
InChI
InChI=1S/C25H25F3N4O6/c1-24(15-31-14-22(32(33)34)29-23(31)38-24)16-35-18-4-2-17(3-5-18)30-12-10-20(11-13-30)36-19-6-8-21(9-7-19)37-25(26,27)28/h2-9,14,20H,10-13,15-16H2,1H3/t24-/m1/s1
IUPAC Name
1-(4-{[(2R)-2-methyl-6-nitro-2H,3H-imidazo[2,1-b][1,3]oxazol-2-yl]methoxy}phenyl)-4-[4-(trifluoromethoxy)phenoxy]piperidine
SMILES
C[C@]1(COC2=CC=C(C=C2)N2CCC(CC2)OC2=CC=C(OC(F)(F)F)C=C2)CN2C=C(N=C2O1)[N+]([O-])=O

Pharmacology

Indication

Indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability [6].

Associated Conditions
Pharmacodynamics

The minimum inhibitory concentrations (MIC) of delamanid against Mycobacterium tuberculosis isolates ranges from 0.006 to 0.024 g/mL [2]. Among non-tuberculosis mycobacteria, delamanid has in vitro activity against M. kansasii and M. bovis [2]. Delamanid has no in vitro activity against Gram negative or positive bacterial species and does not display cross-resistance to other anti-tuberculosis drugs [6]. In murine models of chronic tuberculosis, the reduction of M. tuberculosis colony counts by delamanid was demonstrated in a dose-dependent manner [2]. Repeated dosing of delamanid may cause QTc-prolongation via inhibition of cardiac potassium channel (hERG channel), and this effect is mostly contributed by the main metabolite of delamanid, DM-6705 [6, 2]. Animal studies indicate that delamanid may attenuate vitamin K-dependent blood clotting, increase prothrombin time (PT), and activated partial thromboplastin time (APTT) [2].

Mechanism of action

Delamanid is a prodrug that requires biotransformation via via the mycobacterial F420 coenzyme system, including the deazaflavin dependent nitroreductase (Rv3547), to mediate its antimycobacterial activity [2] against both growing and nongrowing mycobacteria [3]. Mutations in one of five coenzyme F420 genes, fgd, Rv3547, fbiA, fbiB, and fbiC has been proposed as the mechanism of resistance to delamanid [2]. Upon activation, the radical intermediate formed between delamanid and desnitro-imidazooxazole derivative [5] is thought to mediate antimycobacterial actions via inhibition of methoxy-mycolic and keto-mycolic acid synthesis, leading to depletion of mycobacterial cell wall components and destruction of the mycobacteria [6]. Nitroimidazooxazole derivative is thought to generate reactive nitrogen species, including nitrogen oxide (NO). However unlike isoniazid, delamanid does not alpha-mycolic acid [2].

Absorption

Following a single oral dose administration of 100 mg delamanid, the peak plasma concentration was 135 ng/mL [4]. Steady-state concentration is reached after 10-14 days [5]. Delamanid plasma exposure increases less than proportionally with increasing dose. In animal models (dog, rat, mouse), the oral bioavailability of delamanid was reported to be 35%–60% [2]. The absolute oral bioavailability in humans is estimated to range from 25 to 47% [3]. Oral bioavailability in humans is enhanced when administered with a standard meal, by about 2.7 fold compared to fasting conditions [6] because delamanid exhibits poor water solubility [3].

Volume of distribution

The apparent volume of distribution (Vz/F) is 2,100 L. Pharmacokinetic data in animals have shown excretion of delamanid and/or its metabolites into breast milk. In lactating rats, the Cmax for delamanid in breast milk was 4-fold higher than that of the blood [6].

Protein binding

Delamanid highly binds to all plasma proteins with a binding to total proteins of ≥99.5% [6].

Metabolism

Delamanid predominantly undergoes metabolism by albumin and to a lesser extent, CYP3A4. [6]. The metabolism of delamanid may also be mediated by hepatic CYP1A1, CYP2D6, and CYP2E1 to a lesser extent [31966]. Four major metabolites (M1–M4) have been identified in plasma in patients receiving delamanid where M1 and M3 accounts for 13%–18% of the total plasma exposure in humans [4]. While they do not retain significant pharmacological activity, they may still contribute to QT prolongation [3]. This is especially true for the main metabolite of delamanid, M1 (DM-6705) [2, 3].

Delamanid is predominantly metabolized by serum albumin to form M1 (DM-6705) via hydrolytic cleavage of the 6-nitro-2,3-dihydroimidazo[2,1-b] oxazole moiety. The formation of this major metabolite is suggested to be a crucial starting point in the metabolic pathway of delamanid [4]. M1 (DM-6705) can be further catalyzed by three pathways. In the first metabolic pathway, DM-6705 undergoes hydroxylation of the oxazole moiety to form M2 ((4RS,5S)-DM-6720), followed by CYP3A4-mediated oxidation of hydroxyl group and tautomerization of oxazole to an imino-ketone metabolite, M3 ((S)-DM-6718) [4]. The second metabolic pathway involves the hydrolysis and deamination of the oxazole amine to form M4 (DM-6704) followed by hydroxylation to M6 ((4R,5S)-DM-6721) and M7 ((4S,5S)-DM-6722) and oxidation of oxazole to another ketone metabolite, M8 ((S)-DM-6717) [4]. The third pathway involves the hydrolytic cleavage of the oxazole ring to form M5 (DM-6706) [4].

Route of elimination

Delamanid is excreted primarily in the stool, with less than 5% excretion in the urine [3].

Half life

The half life ranges from 30 to 38 hours [6].

Clearance
Not Available
Toxicity

While there have been no cases of delamanid overdose, some adverse reactions were observed at a higher frequency and the rate of QT prolongation increased in a dose-related manner. Treatment of overdose should involve immediate measures to remove delamanid from the gastrointestinal tract and supportive care as required. Frequent ECG monitoring should be performed [6].

Studies of genotoxicity and carcinogenic potential reveal no significant effects on humans. Delamanid and/or its metabolites have the potential to affect cardiac repolarisation via blockade of hERG potassium channels. During repeat-dose studies in dogs, foamy macrophages were observed in lymphoid tissue of various organs with delamanid treatment although clinical relevance of this finding was not established. Repeat-dose toxicity studies in rabbits revealed an inhibitory effect of delamanid and/or its metabolites on clotting factors II, VII, IX, and X via inhibition of vitamin K production [6, 2]. Embryo-fetal toxicity was observed at maternally toxic dosages in reproductive studies involving rabbits [6].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
Acetyl sulfisoxazoleThe metabolism of Delamanid can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AmiodaroneAmiodarone may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
AnagrelideAnagrelide may increase the QTc-prolonging activities of Delamanid.Approved
ApalutamideThe serum concentration of Delamanid can be decreased when it is combined with Apalutamide.Approved, Investigational
AprepitantThe serum concentration of Delamanid can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideArsenic trioxide may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
AstemizoleAstemizole may increase the QTc-prolonging activities of Delamanid.Approved, Withdrawn
AtazanavirAtazanavir may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
AtomoxetineThe metabolism of Delamanid can be decreased when combined with Atomoxetine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Delamanid.Approved
BepridilBepridil may increase the QTc-prolonging activities of Delamanid.Approved, Withdrawn
BesifloxacinBesifloxacin may increase the QTc-prolonging activities of Delamanid.Approved
BoceprevirBoceprevir may increase the QTc-prolonging activities of Delamanid.Approved, Withdrawn
BortezomibThe metabolism of Delamanid can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Delamanid can be decreased when it is combined with Bosentan.Approved, Investigational
CarbamazepineThe metabolism of Delamanid can be increased when combined with Carbamazepine.Approved, Investigational
CeritinibCeritinib may increase the QTc-prolonging activities of Delamanid.Approved
ChloroquineChloroquine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Vet Approved
ChlorpromazineChlorpromazine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Vet Approved
CilostazolCilostazol may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
CisaprideCisapride may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Withdrawn
CitalopramCitalopram may increase the QTc-prolonging activities of Delamanid.Approved
ClarithromycinClarithromycin may increase the QTc-prolonging activities of Delamanid.Approved
ClemastineThe metabolism of Delamanid can be decreased when combined with Clemastine.Approved, Investigational
ClotrimazoleThe metabolism of Delamanid can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatCobicistat may increase the QTc-prolonging activities of Delamanid.Approved
CocaineCocaine may increase the QTc-prolonging activities of Delamanid.Approved, Illicit
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Delamanid.Approved, Investigational
CrizotinibThe metabolism of Delamanid can be decreased when combined with Crizotinib.Approved
CurcuminCurcumin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
CyclosporineThe metabolism of Delamanid can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Delamanid can be decreased when it is combined with Dabrafenib.Approved, Investigational
DarunavirDarunavir may increase the QTc-prolonging activities of Delamanid.Approved
DasatinibThe serum concentration of Delamanid can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Delamanid can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Delamanid can be decreased when combined with Delavirdine.Approved
DifloxacinDifloxacin may increase the QTc-prolonging activities of Delamanid.Vet Approved
DihydroergotamineThe metabolism of Delamanid can be decreased when combined with Dihydroergotamine.Approved, Investigational
DiltiazemThe metabolism of Delamanid can be decreased when combined with Diltiazem.Approved, Investigational
DisopyramideDisopyramide may increase the QTc-prolonging activities of Delamanid.Approved
DofetilideDofetilide may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DomperidoneDomperidone may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the QTc-prolonging activities of Delamanid.Approved
DoxycyclineThe metabolism of Delamanid can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneDronedarone may increase the QTc-prolonging activities of Delamanid.Approved
DroperidolDroperidol may increase the QTc-prolonging activities of Delamanid.Approved, Vet Approved
EnoxacinEnoxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
EnzalutamideThe serum concentration of Delamanid can be decreased when it is combined with Enzalutamide.Approved
ErythromycinErythromycin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Vet Approved
EscitalopramEscitalopram may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
FlecainideFlecainide may increase the QTc-prolonging activities of Delamanid.Approved, Withdrawn
FleroxacinFleroxacin may increase the QTc-prolonging activities of Delamanid.Approved
FluconazoleFluconazole may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
FluvoxamineThe metabolism of Delamanid can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Delamanid can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Delamanid can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Delamanid can be increased when combined with Fosphenytoin.Approved, Investigational
Fusidic AcidThe serum concentration of Delamanid can be increased when it is combined with Fusidic Acid.Approved, Investigational
GarenoxacinGarenoxacin may increase the QTc-prolonging activities of Delamanid.Investigational
GatifloxacinGatifloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
GrepafloxacinGrepafloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Withdrawn
HalofantrineHalofantrine may increase the QTc-prolonging activities of Delamanid.Approved
HaloperidolHaloperidol may increase the QTc-prolonging activities of Delamanid.Approved
IbutilideIbutilide may increase the QTc-prolonging activities of Delamanid.Approved
IdelalisibIdelalisib may increase the QTc-prolonging activities of Delamanid.Approved
ImatinibThe metabolism of Delamanid can be decreased when combined with Imatinib.Approved
IndinavirIndinavir may increase the QTc-prolonging activities of Delamanid.Approved
IsavuconazoleThe serum concentration of Delamanid can be increased when it is combined with Isavuconazole.Approved, Investigational
IsavuconazoniumThe metabolism of Delamanid can be decreased when combined with Isavuconazonium.Approved, Investigational
IsradipineThe metabolism of Delamanid can be decreased when combined with Isradipine.Approved, Investigational
ItraconazoleItraconazole may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
IvacaftorThe serum concentration of Delamanid can be increased when it is combined with Ivacaftor.Approved
KetoconazoleKetoconazole may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
Levomethadyl AcetateLevomethadyl Acetate may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
LomefloxacinLomefloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
LopinavirLopinavir may increase the QTc-prolonging activities of Delamanid.Approved
LorpiprazoleThe serum concentration of Delamanid can be increased when it is combined with Lorpiprazole.Approved
LovastatinThe metabolism of Delamanid can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Delamanid can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Delamanid can be increased when combined with Lumacaftor.Approved
MesoridazineMesoridazine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
MethadoneMethadone may increase the QTc-prolonging activities of Delamanid.Approved
MethotrimeprazineMethotrimeprazine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
MifepristoneThe serum concentration of Delamanid can be increased when it is combined with Mifepristone.Approved, Investigational
MitotaneThe serum concentration of Delamanid can be decreased when it is combined with Mitotane.Approved
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
NefazodoneNefazodone may increase the QTc-prolonging activities of Delamanid.Approved, Withdrawn
NelfinavirNelfinavir may increase the QTc-prolonging activities of Delamanid.Approved
NetupitantThe serum concentration of Delamanid can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe metabolism of Delamanid can be increased when combined with Nevirapine.Approved
NilotinibThe metabolism of Delamanid can be decreased when combined with Nilotinib.Approved, Investigational
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Delamanid.Approved
OfloxacinOfloxacin may increase the QTc-prolonging activities of Delamanid.Approved
OlaparibThe metabolism of Delamanid can be decreased when combined with Olaparib.Approved
OndansetronOndansetron may increase the QTc-prolonging activities of Delamanid.Approved
OrbifloxacinOrbifloxacin may increase the QTc-prolonging activities of Delamanid.Vet Approved
OsimertinibThe serum concentration of Delamanid can be increased when it is combined with Osimertinib.Approved
OxaliplatinOxaliplatin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
PalbociclibThe serum concentration of Delamanid can be increased when it is combined with Palbociclib.Approved, Investigational
PapaverinePapaverine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
PazufloxacinPazufloxacin may increase the QTc-prolonging activities of Delamanid.Investigational
PefloxacinPefloxacin may increase the QTc-prolonging activities of Delamanid.Approved
PentamidinePentamidine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
PentobarbitalThe metabolism of Delamanid can be increased when combined with Pentobarbital.Approved, Investigational, Vet Approved
PhenobarbitalThe metabolism of Delamanid can be increased when combined with Phenobarbital.Approved, Investigational
PhenytoinThe metabolism of Delamanid can be increased when combined with Phenytoin.Approved, Vet Approved
PimozidePimozide may increase the QTc-prolonging activities of Delamanid.Approved
PitolisantThe serum concentration of Delamanid can be decreased when it is combined with Pitolisant.Approved, Investigational
PosaconazolePosaconazole may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Vet Approved
PrimidoneThe metabolism of Delamanid can be increased when combined with Primidone.Approved, Vet Approved
ProbucolProbucol may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
ProcainamideProcainamide may increase the QTc-prolonging activities of Delamanid.Approved
PropofolPropofol may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Vet Approved
PrulifloxacinPrulifloxacin may increase the QTc-prolonging activities of Delamanid.Investigational
QuinidineQuinidine may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
RanolazineThe metabolism of Delamanid can be decreased when combined with Ranolazine.Approved, Investigational
RifabutinThe metabolism of Delamanid can be increased when combined with Rifabutin.Approved, Investigational
RifampicinThe metabolism of Delamanid can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Delamanid can be increased when combined with Rifapentine.Approved, Investigational
RoxithromycinRoxithromycin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Delamanid can be decreased when combined with Rucaparib.Approved, Investigational
RufloxacinRufloxacin may increase the QTc-prolonging activities of Delamanid.Experimental
SaquinavirSaquinavir may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
SarafloxacinSarafloxacin may increase the QTc-prolonging activities of Delamanid.Vet Approved, Withdrawn
SarilumabThe therapeutic efficacy of Delamanid can be decreased when used in combination with Sarilumab.Approved, Investigational
SevofluraneSevoflurane may increase the QTc-prolonging activities of Delamanid.Approved, Vet Approved
SildenafilThe metabolism of Delamanid can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Delamanid can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Delamanid can be increased when it is combined with Simeprevir.Approved
SitafloxacinSitafloxacin may increase the QTc-prolonging activities of Delamanid.Experimental, Investigational
SotalolSotalol may increase the QTc-prolonging activities of Delamanid.Approved
SparfloxacinSparfloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
St. John's WortThe serum concentration of Delamanid can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Delamanid can be increased when it is combined with Stiripentol.Approved
SulfisoxazoleThe metabolism of Delamanid can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
SultoprideSultopride may increase the QTc-prolonging activities of Delamanid.Experimental
Technetium Tc-99m ciprofloxacinTechnetium Tc-99m ciprofloxacin may increase the QTc-prolonging activities of Delamanid.Investigational
TelaprevirTelaprevir may increase the QTc-prolonging activities of Delamanid.Approved, Withdrawn
TelithromycinTelithromycin may increase the QTc-prolonging activities of Delamanid.Approved
TemafloxacinTemafloxacin may increase the QTc-prolonging activities of Delamanid.Withdrawn
TerfenadineTerfenadine may increase the QTc-prolonging activities of Delamanid.Approved, Withdrawn
TerlipressinTerlipressin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
TerodilineTerodiline may increase the QTc-prolonging activities of Delamanid.Experimental
ThioridazineThioridazine may increase the QTc-prolonging activities of Delamanid.Approved, Withdrawn
TiclopidineThe metabolism of Delamanid can be decreased when combined with Ticlopidine.Approved
TocilizumabThe serum concentration of Delamanid can be decreased when it is combined with Tocilizumab.Approved
TrovafloxacinTrovafloxacin may increase the QTc-prolonging activities of Delamanid.Approved, Investigational, Withdrawn
VandetanibVandetanib may increase the QTc-prolonging activities of Delamanid.Approved
VemurafenibThe serum concentration of Delamanid can be decreased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Delamanid can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Delamanid can be decreased when combined with Verapamil.Approved
VoriconazoleVoriconazole may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
ZiprasidoneThe metabolism of Delamanid can be decreased when combined with Ziprasidone.Approved
Food Interactions
Not Available

References

General References
  1. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, Geiter LJ, Manissero D, Wells CD: Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013 Jun;41(6):1393-400. doi: 10.1183/09031936.00125812. Epub 2012 Sep 27. [PubMed:23018916]
  2. Lewis JM, Sloan DJ: The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag. 2015 May 13;11:779-91. doi: 10.2147/TCRM.S71076. eCollection 2015. [PubMed:25999726]
  3. Szumowski JD, Lynch JB: Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther. 2015 Jan 29;9:677-82. doi: 10.2147/DDDT.S60923. eCollection 2015. [PubMed:25678771]
  4. Sasahara K, Shimokawa Y, Hirao Y, Koyama N, Kitano K, Shibata M, Umehara K: Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo. Drug Metab Dispos. 2015 Aug;43(8):1267-76. doi: 10.1124/dmd.115.064527. Epub 2015 Jun 8. [PubMed:26055620]
  5. Xavier AS, Lakshmanan M: Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014 Jul;5(3):222-4. doi: 10.4103/0976-500X.136121. [PubMed:25210407]
  6. Deltyba, INN-Delamanid - European Medicines Agency - Europa EU [Link]
External Links
ChemSpider
4981055
ChEBI
134742
ChEMBL
CHEMBL218650
Wikipedia
Delamanid
ATC Codes
J04AK06 — Delamanid
MSDS
Download (218 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentPediatric / Tuberculosis, Multidrug Resistant1
1, 2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2Active Not RecruitingTreatmentPediatric / Tuberculosis, Multidrug Resistant1
2CompletedTreatmentExtensively Drug-Resistant Tuberculosis / Tuberculosis, Multidrug Resistant / Tuberculosis, Pulmonary1
2CompletedTreatmentTuberculosis1
2CompletedTreatmentTuberculosis, Multidrug Resistant1
2CompletedTreatmentTuberculosis, Pulmonary1
2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis1
2RecruitingTreatmentTuberculosis, Multidrug Resistant1
3CompletedTreatmentTuberculosis, Multidrug Resistant1
3Not Yet RecruitingPreventionTuberculosis, MDR1
3RecruitingTreatmentTuberculosis, Multidrug Resistant1
3WithdrawnTreatmentTuberculosis Multi Drug Resistant Active1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral50 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00222 mg/mLALOGPS
logP5.71ALOGPS
logP6.14ChemAxon
logS-5.4ALOGPS
pKa (Strongest Basic)5.51ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area101.12 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity124.85 m3·mol-1ChemAxon
Polarizability51.59 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Piperidines
Sub Class
Phenylpiperidines
Direct Parent
Phenylpiperidines
Alternative Parents
Aminophenyl ethers / Aniline and substituted anilines / Dialkylarylamines / Nitroaromatic compounds / Nitroimidazoles / Phenoxy compounds / Alkyl aryl ethers / N-substituted imidazoles / Imidolactams / Heteroaromatic compounds
show 10 more
Substituents
Phenylpiperidine / Aminophenyl ether / Phenoxy compound / Nitroaromatic compound / Nitroimidazole / Phenol ether / Tertiary aliphatic/aromatic amine / Dialkylarylamine / Aniline or substituted anilines / Alkyl aryl ether
show 32 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)
Pharmacological action
Yes
Actions
Substrate
General Function
Involved in a F420-dependent anti-oxidant mechanism that protects M.tuberculosis against oxidative stress and bactericidal agents. Catalyzes the F420H(2)-dependent two-electron reduction of quinones to dihydroquinones, thereby preventing the formation of cytotoxic semiquinones obtained by the one-electron reduction pathway (PubMed:23240649). In vitro, catalyzes the reduction of both benzoquinone and naphthoquinone analogs; since menaquinone is the sole quinone electron carrier in the respiratory chain in M.tuberculosis, the physiological electron acceptor for Fqr-mediated F420H(2) oxidation is therefore likely to be the endogenous menaquinone found in the membrane fraction of M.tuberculosis (PubMed:23240649). Is able to use F420 species with two and five glutamate residues in its polyglutamate tail (PubMed:22023140). Cannot use NADH or NADPH instead of F420H(2) as the electron donor (PubMed:23240649).
Specific Function
Coenzyme f420 binding
Gene Name
ddn
Uniprot ID
P9WP15
Uniprot Name
Deazaflavin-dependent nitroreductase
Molecular Weight
17370.87 Da
References
  1. Lewis JM, Sloan DJ: The role of delamanid in the treatment of drug-resistant tuberculosis. Ther Clin Risk Manag. 2015 May 13;11:779-91. doi: 10.2147/TCRM.S71076. eCollection 2015. [PubMed:25999726]
  2. Szumowski JD, Lynch JB: Profile of delamanid for the treatment of multidrug-resistant tuberculosis. Drug Des Devel Ther. 2015 Jan 29;9:677-82. doi: 10.2147/DDDT.S60923. eCollection 2015. [PubMed:25678771]
  3. Xavier AS, Lakshmanan M: Delamanid: A new armor in combating drug-resistant tuberculosis. J Pharmacol Pharmacother. 2014 Jul;5(3):222-4. doi: 10.4103/0976-500X.136121. [PubMed:25210407]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Deltyba, INN-Delamanid - European Medicines Agency - Europa EU [Link]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Deltyba, INN-Delamanid - European Medicines Agency - Europa EU [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Deltyba, INN-Delamanid - European Medicines Agency - Europa EU [Link]

Drug created on October 17, 2016 15:29 / Updated on July 02, 2018 19:25